Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Launched by ANHUI PROVINCIAL HOSPITAL · Jul 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment combination of two medications, donafenib and envafolimab, for patients who have a high risk of their liver cancer (specifically hepatocellular carcinoma) coming back after surgery. The goal is to see how effective and safe this combination is in preventing cancer recurrence in individuals who have already undergone a major surgery to remove the cancer.

To participate in this study, patients must be between 18 and 80 years old and have had their liver cancer surgically removed with clear margins, meaning no cancer was left behind. They also need to have certain risk factors that make them more likely to have the cancer return, such as having a large tumor or multiple tumors. Participants will receive the treatment and will be monitored closely for any side effects and to see how well the treatment works. This trial is currently recruiting participants, so those who meet the criteria and are interested can join and contribute to important research in fighting liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-80 years old, male and female.
• • Subjects voluntarily enrolled in this study and signed the informed consent, good compliance and co-operated with the follow-up.
• • Primary hepatocellular carcinoma with postoperative histopathological diagnosis of HCC and negative margins.
• • Presence of any of the following high-risk factors for recurrence: ① tumor size ≥5.0cm combined with microvascular invasion; ② number of tumors ≥3; ③ presence of portal vein cancer thrombus (vp1 or vp2 type).
• • No recurrence of metastasis confirmed by imaging examination 3-7 weeks after surgery.
• • ECOG score of 0-1.
• • Expected survival ≥ 3 months.
• • Child-Pugh score ≤ 7.
• • Subjects with no previous antitumour therapy (except antiviral therapy)
• • No extra-hepatic metastases or lymph node metastases.
• • No significant abnormality in routine laboratory tests (blood test, liver and kidney function, coagulation function, etc.): (1) Criteria for routine blood tests need to be met (no blood and blood products transfusion within 14 days): a. Absolute neutrophil value (ANC) ≥ 1.5\*10\^9/L; b. Haemoglobin (HGB) ≥ 90g/L; c. Platelet count (PLT) ≥ 75\*10\^9/L. (2) Biochemical tests need to meet the following criteria: a. Serum albumin (ALB) ≥ 35g/L; b. Serum total bilirubin (TBIL) \< 1.5\*Upper Limit of Normal (ULN); c. Serum glutamic transaminase (AST), alanine aminotransferase (ALT) \< 2.5\*ULN; d. Serum creatinine ≤ 1.5\*ULN.
• Exclusion Criteria:
• • Previous histologically/cytologically confirmed fibroplaque-containing hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components.
• • Histologically confirmed positive resection margin (R1 resection), presence of lymph node metastasis or extrahepatic metastasis.
• • Previous or current malignancy other than hepatocellular carcinoma.
• • History of hepatic encephalopathy or history of liver transplantation.
• • Previous history of allergy to any component of the test drug: Envafolimab monoclonal antibody, donafini.
• • Subjects with poorly controlled persistent postoperative pleural, abdominal or pericardial effusion.
• • Previous antitumour therapy (except antiviral therapy).
• • History of interstitial lung disease (except radiation pneumonitis not treated with hormones), non-infectious pneumonia.
• • Presence of any active autoimmune disease or history of autoimmune disease in the subject (e.g., the following, but not limited to: autoimmune hepatitis, interstitial pneumonitis, uveitis, enterocolitis, hepatitis, pituitary gland inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism subjects with vitiligo or asthma that has been in complete remission in childhood and does not require any intervention in adulthood may be enrolled subjects with asthma that requires medical intervention with bronchodilators cannot be included).
• • Subjects who are on immunosuppressive, or systemic, or absorbable topical hormone therapy for immunosuppression (dose \>10mg/day prednisone or other equipotent hormone) and continue to use it within 2 weeks prior to enrolment.
• • A serious infection (CTCAE \> grade 2) such as severe pneumonia, bacteraemia, or infectious co-morbidities requiring hospitalisation has occurred 4 weeks prior to the first use of study drug.
• • Subjects who have experienced acute cardiovascular disease such as acute cerebral infarction, acute coronary syndrome, etc. within 1 month, with cardiovascular clinical symptoms or disease not well controlled.
• • According to NYHA standard, grade III to IV cardiac insufficiency, or cardiac ultrasound examination suggests that the left ventricular ejection fraction (LVEF) \<50%
• • Uncontrollable hypertension with treated systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg, hypertensive crisis or history of hypertensive encephalopathy
• • Patients with a definite tendency to gastrointestinal bleeding, including the following: patients with locally active ulcerative lesions and fecal occult blood {(++) may not be enrolled} those with a history of black stools and vomiting of blood within 2 months.
• • Those with abnormal coagulation function (INR\>1.5 APTT\>1.5 ULN) and bleeding tendency.
• • Prolonged unhealed wounds or fractures major surgical procedures or severe traumatic injuries, fractures or ulcers within 4 weeks.
• • Subjects with congenital or acquired immune deficiency (e.g., HIV-infected individuals), or active hepatitis (Hepatitis B reference: HBV DNA test value exceeds the upper limit of normal Hepatitis C reference: HCV viral titre or RNA test value exceeds the upper limit of normal).
• • Patients with a history of psychotropic substance abuse that cannot be stopped or patients with mental disorders.
• • Patients with concomitant illnesses that, in the investigator's judgement, are a serious hazard to patient safety or interfere with the patient's ability to complete the study.
• • Pregnant women, lactating women, and women of childbearing age who are not using adequate contraception.
• • In the judgement of the investigator, Patients who are not suitable for inclusion.